Search PubMed⌕ Search

Biomedical subjects

N Atkins

Publications and source records attributed to N Atkins.

77 records · Page 5Linked to original sources
PubMedDate not supplied

Renal transplantation performed across a positive crossmatch: a single centre experience.

UNLABELLED: The importance of certain positive crossmatches (CM+) in kidney transplantation remains controversial. Fifty consecutive kidney transplants were performed across a CM+ between Jan. 1990-April 1994. In 19 cases there was an isolated B-cell CM+ (Group I), in 24 an historic T-cell IgM CM+ (Group II) and in 7 an historic T-cell IgG CM+ (Group III). Comparing groups I:II:III: early acute rejection affected 32%, 42%, 57% of grafts; mean serum creatinine at 3 months was 166, 150, 229 umol/l (p < 0.05); 1 yr graft survival was 95 per cent, 96 per cent, 71 per cent (p = 0.09). In group III both graft losses were in the setting of an additional current B-cell CM+. CONCLUSIONS: Transplantation performed in either the presence of an isolated B-cell CM+ or in the presence of an historic T-cell IgM CM+ was associated with acceptable outcomes at 1 yr. An historic T-cell IgG CM+ was confirmed as a contraindication to transplantation in most circumstances, especially when coupled with a current B-cell CM+.

Adult↗
PubMedDate not supplied

The quest for better validation: a critical comparison of the AAMI and BHS validation protocols for ambulatory blood pressure measurement systems.

Two validation procedures are currently available for the evaluation of ambulatory blood pressure measurement systems--the standard of the Association for the Advancement of Medical Instrumentation (AAMI) and the protocol of the British Hypertension Society (BHS). Both are in the process of revision. Four systems for measuring 24-hour ambulatory blood pressure--SpaceLabs 90207, Novacor DIASYS 200, Del Mar Avionics Pressurometer IV, and Takeda TM-2420--were evaluated according to the BHS protocol, which incorporates many of the features of the AAMI standard, under similar conditions by the same personnel and in the same subjects, so as to examine the relative merits of the two evaluation procedures. Three recorders of each model were subjected to a before-use inter-device variability test, followed by an in-use phase and an after-use inter-device variability test. The main validation test was carried out in 86 subjects with a wide range of pressures, the results being analyzed according to the BHS grading system and the AAMI validation criteria. The SpaceLabs 90207 and the DIASYS 200 achieved B and C grades, respectively, according to the BHS protocol and also satisfied the AAMI criteria for accuracy. The Pressurometer IV achieved a Grade C rating for systolic pressure and a Grade D rating for diastolic pressure and the Takeda TM-2420 achieved Grade D ratings for both systolic pressure and diastolic pressure. Both these devices failed to fulfil the AAMI criteria for accuracy and both failed to function in the main validation test and had to be replaced.(ABSTRACT TRUNCATED AT 250 WORDS)

Ambulatory Care↗
PubMedDate not supplied

Lectin binding to normal and malignant breast tissue.

The major carbohydrate groups expressed by normal breast epithelium and primary breast cancers were identified by lectins, using an immunoperoxidase method on paraffin sections. All the lectins (pokeweed, lotus, wheatgerm, peanut, helix, bandeiraea 1, soybean and concanavalin A) bound to breast cancer cells with a variable cytoplasmic, luminal surface or intercellular pattern. Not all cancer cells bound lectins, suggesting sub-populations within individual tumours. On normal breast sections all lectins, with the exception of concanavalin A, bound to the luminal surface of the lining epithelial cells or to myoepithelial cells and showed some differences between acinar and ductal epithelium. The main difference in lectin binding between normal and malignant cells was the transition from luminal surface to cytoplasmic binding to lectins by cancers. In addition, quantitative differences were noted, particularly for concanavalin A which bound to cancer cells but not to normal epithelium.

Binding Sites↗